Boston Scientific Corporation

BSX-PA

Get informed when a big investor buys or sells

Market Cap$175.45B

Close$

Compare to Similar Companies

	P/E Ratio	Dividends	Return on Equity	Price-to-Sales	Debt-to-Equity
Boston Scientific Corporation	18.8	-	14%	8.7	0.4

Earnings Call Q2 2026

July 29, 2026 - AI Summary

Q2 performance beat; EPS strength driven by tax items - Total company organic sales +7% YoY, ahead of the 5%–7% guide. - Adjusted EPS $0.86 (+15% YoY), beating the high end of guidance ($0.82–$0.84), mainly from favorable discrete tax results. - Adjusted operating margin: 28.4%; adjusted gross margin 70.3% (up 80 bps YoY). - Notable GAAP items: product liability charge (~$75M) and tariff refunds recognized (~$80M).

Major forecast reset: 2026 outlook downgraded (pressure in 2 key franchises) - Updated full-year 2026 organic revenue: +5% to +6% (previously guided higher), adjusted EPS: $3.28 to $3.32 (+7% to +8%). - Q3 2026 guide: organic revenue +3% to +5%; adjusted EPS $0.80–$0.82. - Management says second half is more pressured than expected; the guidance reduction is concentrated in: - WATCHMAN: U.S. market slowed sharply due to compounding clinical evidence impacting referral patterns. - Electrophysiology (EP): greater competitive share movement in the U.S. than anticipated.

WATCHMAN: mid/high-single-digit declines expected in 2H26; no near-term improvement assumed for 2027 - Q2 WATCHMAN: +4%, with international +18% and U.S. +3%. - Concomitant adoption accelerating: ~1/3 of U.S. procedures concomitant; concomitant procedures +60% YoY and +11% sequential vs Q1. - For the rest of 2026: - Global WATCHMAN growth flat to low-single digits (full year). - 2H26 global decline mid- to high-single digits YoY. - U.S. Q3 expected to decline mid-single digits sequentially; full-year U.S. flat growth. - 2027 guidance posture: management explicitly assumes market dynamics do not improve in 2027 (even while expecting actions to help over time).

Exclusive for Stockcircle Pro members

Share Statistics

Market cap	$175.45 Billion
Enterprise Value	$184.95 Billion
Dividend Yield	$- (-)
Earnings per Share	$1.96
Beta	0.8
Outstanding Shares	1,477,600,000

Return

Return on Equity	14.18%
Return on Assets	8.27%
Return on Invested Capital	10.58%

Valuation & Multiples

P/E Ratio	18.84
PEG	136.52
Price to Sales	8.73
Price to Book Ratio	7.19
Enterprise Value to Revenue	8.81
Enterprise Value to EBIT	43.95
Enterprise Value to Net Income	50
Total Debt to Enterprise	0.06
Debt to Equity	0.43

Revenue Sources

No data

Insider Trades

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

ESG Score

No data

About Boston Scientific Corporation

45,000 employees

CEO: Michael F. Mahoney

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The com...

Relevant Senate Committees

Joint Committee on Taxation

Determines tax policy on medical devices and R&D credits, which significantly impacts the company's financial performance and capital allocation.

Finance

Controls Medicare and Medicaid reimbursement policy, the single largest driver of revenue and pricing for medical device companies.

Appropriations

Determines the actual funding levels for healthcare agencies and research grants, providing members with non-public knowledge of future government spending.

Health, Education, Labor, and Pensions

Directly regulates the FDA, which controls the approval process for all of the company's medical technologies.

Special Committee on Aging

The committee's focus on Medicare and conditions affecting the elderly directly aligns with Boston Scientific's core cardiac and neuro patient demographics.

Veterans' Affairs

The VA is a major purchaser of cardiovascular and surgical devices; committee decisions directly impact the company's revenue from the public sector.